Cancer Research Horizons, the innovation arm of Cancer Research UK, has appointed three members to its newly created Therapeutic Innovation board intended to steer its drug discovery strategy. The board members are: Carlos Garcia-Echeverria, who has led drug discovery and development teams including at EQRx, Sanofi and Novartis; Katharina Kreymborg, senior vice president at Curie.Bio, and Karen Lackey, chief executive officer of X-Chem and with previous senior roles at Roche, GSK and Evotec. The inaugural chair of the board is Christoph Lengauer, co-founder and chief scientific officer of Curie.Bio and an adjunct associate professor at John Hopkins University, US.
Cancer Research Horizons announced the appointments on 22 August 2024.
Copyright 2024 Evernow Publishing Ltd.